Precision Medicine Engine
HelixGroups: From De Novo DNA to Predictive Drug Certification
Standard healthcare prescribes for the statistical average and reacts only after disease manifests. Yet patients naturally belong to multiple overlapping genetic clusters simultaneously. Our machine-learning and large-language-model pipelines analyze high-fidelity, de novo assembled HiFi DNA and proteomic profiles to classify individuals into HelixGroups — capturing structural variants, rare insertions, and non-linear multi-gene interactions that govern drug metabolism, efficacy, and adverse-reaction risk.
Pharmaceutical sponsors can certify compounds against specific HelixGroups and recruit clinical-trial cohorts using zero-knowledge eligibility proofs on helixstreet.io — proving that participants match exact genetic inclusion criteria without ever exposing raw patient DNA.